Takeda Announces Arcotatug Tavatecan (TAK-921) Has Been Granted SAKIGAKE Designation by Japan Ministry of Health, Labour and Welfare (MHLW)
Takeda Announces Arcotatug Tavatecan (TAK-921) Has Been Granted SAKIGAKE Designation by Japan Ministry of Health, Labour and Welfare (MHLW)
Takeda (TSE:4502/NYSE:TAK) announced that arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*1) has been granted SAKIGAKE designation by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the proposed indication of Claudin (CLDN)18.2-positive unresectable advanced or recurrent gastric or gastroesophageal junction adenocarcinoma (G/GEJA) that has progressed after chemotherapy.
SAKIGAKE designation*2 is granted by the MHLW to medicines in development that meet criteria for innovation, efficacy, seriousness of the disease and development plans in Japan. As a medicine granted SAKIGAKE designation, arcotatug tavatecan is eligible for priority regulatory consultation and priority review.
“For patients with advanced G/GEJA, the prognosis remains poor and there is a significant need for new treatment options, particularly as effective therapies become increasingly limited in later lines of treatment,” said Phuong Khanh (P.K.) Morrow, M.D., Head of the Oncology Therapeutic Area Unit at Takeda. “Receiving SAKIGAKE designation is an important milestone for arcotatug tavatecan. We will leverage the priority pathways it provides to work collaboratively with regulatory authorities and advance this investigational medicine as quickly as possible for patients who urgently need new options.”
The designation is based on data from the Phase 3 G-HOPE-001 study (NCT06238843) evaluating arcotatug tavatecan in patients with CLDN18.2-positive previously treated advanced G/GEJA.
The study results were presented in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress.
*1 Innovent refers to arcotatug tavatecan (TAK-921) as IBI343. Under a license and collaboration agreement with Innovent, Takeda holds the rights to develop, manufacture and commercialize arcotatug tavatecan worldwide outside of greater China.
*2 Ministry of Health, Labour and Welfare. SAKIGAKE Designation System. Accessed November 2026.
https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/tp150514-01_00001.html
About Arcotatug Tavatecan
Arcotatug tavatecan is a novel antibody-drug conjugate (ADC) that targets Claudin (CLDN)18.2-expressing tumor cells. CLDN18.2 is a protein typically found in the lining of a healthy stomach but is abnormally expressed on the surface of cancer cells in certain tumors, making it a target for new cancer therapies.1 Arcotatug tavatecan combines an anti-CLDN18.2 antibody with the cytotoxic agent exatecan, a topoisomerase I inhibitor (TOPO1i). It also incorporates an Fc-silenced structural design intended to minimize off-tumor, on-target toxicity.
Arcotatug tavatecan has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with CLDN18.2-positive, locally advanced or metastatic pancreatic cancer who have received two prior systemic therapies. It has also received SAKIGAKE designation by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the proposed indication of CLDN18.2-positive unresectable advanced or recurrent gastric or gastroesophageal junction adenocarcinoma that has progressed after chemotherapy.
About Gastric and Gastroesophageal Junction Adenocarcinoma (G/GEJA)
Gastric cancer is the fifth most common cancer and fifth leading cause of cancer-related deaths worldwide with Japan and China among the highest-incidence regions globally.2,3 Five-year net survival rates vary globally but are approximately 20% to 40%, with markedly poorer rates in patients with advanced disease.4 Treatment options become increasingly limited as the disease progresses, and median overall survival remains less than 10 months for patients receiving later lines of therapy.5 Claudin 18.2, a tight junction protein typically found in healthy gastric tissue but abnormally expressed on the surface of tumor cells in a significant proportion of G/GEJA cancers, has emerged as an important biomarker-driven target for the development of novel precision therapies in this disease.1
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including drug pricing, tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
References
- Sahin U, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624–7634. doi:10.1158/1078-0455.CCR-08-1547
- Yashima K, et al. Gastric Cancer Screening in Japan: A Narrative Review. J Clin Med. 2022;11(15):4337. doi:10.3390/jcm11154337
- Sung H, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. 2026;70090. doi:10.3322/caac.70090
- Allemani C, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023-1075. doi:10.1016/S0140-6736(17)33326-3
- Shitara K, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric or gastro-oesophageal junction cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19(11):1437-1448. doi:10.1016/S1470-2045(18)30739-3